These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28782211)

  • 21. Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers.
    Jensen BT; Dielenseger P; Drudge-Coates L; Flynn K; Hieronymi S; Erik van Muilekom HA; Pieters R; Voss LB
    Eur J Oncol Nurs; 2012 Feb; 16(1):42-53. PubMed ID: 21429796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Gollbach KL; Hayman SR; Kumar S; Lust JA; Rajkumar SV; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Bergsagel PL; Fonseca R; Reeder CB; Stewart AK; Roy V; Dalton RJ; Carr AB; Kademani D; Keller EE; Viozzi CF; Kyle RA
    Mayo Clin Proc; 2006 Aug; 81(8):1047-53. PubMed ID: 16901028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaws and bisphosphonate therapy.
    Ruggiero SL; Drew SJ
    J Dent Res; 2007 Nov; 86(11):1013-21. PubMed ID: 17959890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS; McNulty RM; Kraut EH; Turowski RC
    Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
    Diego R; D'Orto O; Pagani D; Agazzi A; Marzano U; Derada Troletti G; Fontanella W; Pignataro L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):e1-5. PubMed ID: 17197204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
    Patel CG; Yee AJ; Scullen TA; Nemani N; Santo L; Richardson PG; Laubach JP; Ghobrial IM; Schlossman RL; Munshi NC; Anderson KC; Raje NS
    Clin Cancer Res; 2014 Aug; 20(15):3955-61. PubMed ID: 24958808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Mitsiades CS; Rosenblatt J; Mahindra A; Raje N; Munshi N; Anderson KC
    Eur J Haematol; 2012 Jan; 88(1):1-7. PubMed ID: 21991938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bisphosphonates for myeloma patients].
    Miwa A
    Nihon Rinsho; 2007 Dec; 65(12):2315-37. PubMed ID: 18069279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevention and treatment of bisphosphonate-induced jaw bone osteonecrosis. II].
    Fogorv Sz; 2014 Sep; 107(3):106-7. PubMed ID: 25509512
    [No Abstract]   [Full Text] [Related]  

  • 34. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
    Nastro E; Musolino C; Allegra A; Oteri G; Cicciù M; Alonci A; Quartarone E; Alati C; De Ponte FS
    Acta Haematol; 2007; 117(3):181-7. PubMed ID: 17164581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
    Merigo E; Manfredi M; Meleti M; Corradi D; Vescovi P
    J Oral Pathol Med; 2005 Nov; 34(10):613-7. PubMed ID: 16202082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
    Pavkovic M; Petrushevska G; Jovanovic R; Karanfilski O; Cevreska L; Stankovic S; Stojanovic A
    Prilozi; 2010; 31(2):39-49. PubMed ID: 21258276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates: a potential threat to your patients.
    Dreiman BB
    J Indiana Dent Assoc; 2005-2006 Winter; 84(4):4-9. PubMed ID: 16605211
    [No Abstract]   [Full Text] [Related]  

  • 39. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
    Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
    Gallego L; Junquera L
    Br J Oral Maxillofac Surg; 2009 Jan; 47(1):67-8. PubMed ID: 18639371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.